Full-Time
Vice President of Commercial
Idoven
51-200 employees
AI-powered ECG analysis for cardiac risk
No salary listed
Madrid, Spain + 1 more
More locations: Remote in Spain
Remote
Remote within Spain; occasional visits to the Madrid office are available.
 Sales & Account Management (1) |
|---|
Get referred to Idoven
See people who can refer or advise you
- At least 10 years of MedTech business development experience.
- A proven track record of personally leading and closing enterprise deals of €500,000 or more with global pharmaceutical or medical technology companies.
- Deep familiarity with the pharmaceutical and/or medical device commercial landscape; experience in cardiac, imaging, or artificial-intelligence-enabled diagnostics is a strong plus.
- An existing global-level network within pharmaceutical companies, including medical affairs, research and development, digital health, or procurement.
- Experience navigating global budget structures, including MEA and global digital health budgets, and multi-stakeholder enterprise sales cycles.
- Comfort working as an individual contributor in a lean, fast-moving environment, with autonomy and a founder mindset.
- Full professional fluency in Spanish and English.
- A background in healthcare artificial intelligence, Software as a Medical Device, digital health, or a closely adjacent field.
- Own and drive the enterprise sales pipeline, focusing on global pharmaceutical and medical technology companies.
- Close strategic deals in the €500,000–€2M+ range by leveraging established relationships and building new global-level relationships.
- Develop and execute a commercial strategy aligned with the product roadmap and go-to-market vision.
- Work directly with the Chief Operating Officer and Chief Executive Officer to co-develop account strategies, structure deal terms, and lead key negotiations.
- Qualify and refine inbound leads generated by the marketing team and convert them into closed revenue.
- Represent the company at key industry conferences, advisory boards, and pharmaceutical innovation forums.
- As the team grows, contribute to building and mentoring a high-performing commercial team.
- Prior experience selling artificial-intelligence-enabled imaging, echocardiography, radiology artificial intelligence, or electrocardiogram solutions to pharmaceutical companies or health systems.
- Experience at an early- or growth-stage company where commercial processes were built from scratch.
- A network within cardiovascular pharmaceutical companies or clinical research organizations.
Idoven uses Willem™, a cloud-based AI platform that analyzes ECGs to detect cardiovascular diseases. It works by integrating with any ECG hardware and EHRs via APIs, delivering rapid, clinician-ready interpretations. It differentiates itself with a large and diverse ECG database, 80+ patterns, cardiologist-level accuracy, and EU MDR Class IIa certification. Its goal is to prevent cardiovascular disease through early detection and precision medicine by enabling diagnostics speed, risk stratification, and safer drug trials.
Company Size
51-200
Company Stage
Grant
Total Funding
$20.6M
Headquarters
Majadahonda, Spain
Founded
2018
Get referred to Idoven
See people who can refer or advise you
Simplify's Take
What believers are saying
- AstraZeneca and Idoven launched CONCERTO in 2026, expanding pharma credibility.
- ClinicalTrials.gov shows the 5,000-patient AoS-SEDAI study started April 2026.
- Idoven retains backing from Insight Partners, Northzone, Wayra, and EIC grants.
What critics are saying
- CONCERTO and AoS-SEDAI are still recruiting in 2026; commercialization stays unproven.
- Idoven depends on consortium funding and grants, not clear recurring SaaS revenue.
- Abbott, AliveCor, and hospital AI vendors can compress pricing before 2027.
What makes Idoven unique
- Willem received CE Mark Class IIa, covering 22 cardiac patterns in 2026.
- Idoven combines 12-lead ECGs, wearables, and EHR APIs into one device-agnostic platform.
- Its 2026 amyloidosis study claims 96.4% AUC 0.88 from 12-lead ECGs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Health Insurance
Gym Membership
Home Office Stipend
Paid Holidays
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 0%AstraZeneca and Idoven have announced the launch of CONCERTO, a project aimed at improving the early diagnosis of patients with amyloidosis - a rare and frequently underdiagnosed disease due to its wide range of nonspecific symptoms.
Every year, 4 million European citizens die from cardiovascular disease (CVD), and 20% of these deaths are caused by ischemic heart disease. Among the most common forms of ischemic heart disease is acute myocardial infarction, commonly known as a heart attack or heart attack.In order to tackle this acute problem, the ASSIST innovation project consortium, led by the Spanish startup Idoven, has obtained from EIT Health, which is part of the European Institute of Innovation and Technology (EIT), a body of the European Union, €1.5 million in funding over two years to develop the first artificial intelligence-based solution for early diagnosis and accurate triage of acute myocardial infarction.“ASSIST addresses the first cause of death for citizens of the European Union: cardiovascular diseases”, commented Izabel Alfany, interim general director of EIT Health Spain, “the project is aligned with one of the four strategic areas of EIT Health, taking advantage of full potential of health data for innovation, by using existing and new structures to generate and validate the artificial intelligence tool. The ASSIST project is a perfect example of how EIT Health supports start-ups and promotes innovation in health through its international calls and projects so that innovative and disruptive solutions reach the market and improve healthcare and health. of the patients”, adds Alfany.”The implementation of ASSIST is of paramount importance in the current healthcare context, which is marked by the progressive aging of the population and an increasing prevalence of risk factors for acute myocardial infarction. The aim of the consortium is to improve the accuracy and reduce the time to diagnosis of patients with suspected acute myocardial infarction supported by the use of a technological platform called Willem, which employs artificial intelligence models. Through these advances, the ASSIST project aims to achieve a reduction in mortality rates in patients with acute myocardial infarction, which have been shown to decrease proportionally with the reduction of the time from diagnosis to intervention in the most urgent cases (ST-segment elevation myocardial infarction).Dr
Idoven has raised more than $24 million in funding, including Horizon 2020 and EIC Accelerator from European Innovation Council; supported by leading VC firms and Business Angels such as Insight Partners; Northzone; Accel; Wayra, EIT Health; and Iker Casillas.
Thanks to this spirit of collaboration, Idoven can announce that Idoven has worked together with Abbott to analyze the outcome of implementing its AI-based software to improve the accuracy of their ICM devices used for arrhythmia diagnosis.